Aura Biosciences to Participate in Upcoming Investor Conferences
May 25 2022 - 7:00AM
Business Wire
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage
biotechnology company developing a novel class of virus-like drug
conjugate (VDC) therapies for multiple oncology indications, today
announced that members of its executive team will participate in
the following upcoming investor conferences:
- Cowen’s Virtual 3rd Annual Oncology Innovation Summit on
Thursday, June 2, 2022. Fireside chat at 9:00 a.m.
ET.
- Jefferies Global Healthcare Conference at the New York
Marriot Marquis on Wednesday, June 8, 2022. Presentation at
1:30 p.m. ET.
A live webcast of the Cowen fireside chat and Jefferies
presentation will be available on the “Investors & Media” page
under the “Events & Presentations” section of the Company’s
website at https://ir.aurabiosciences.com/events-and-presentations,
where a replay of the webcast will be archived for 90 days
following the presentation date.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company
developing virus-like drug conjugates (VDCs), a novel class of
therapies, for the treatment of multiple oncology indications.
Aura’s lead VDC candidate, AU-011 (belzupacap sarotalocan),
consists of a virus-like particle conjugated with an anti-cancer
agent. AU-011 selectively targets and destroys cancer cells and
activates the immune system with the potential to create
long-lasting anti-tumor immunity. AU-011 is currently in
development for ocular cancers, with an ongoing Phase 2 dose
escalation clinical trial evaluating first-line treatment of
choroidal melanoma, a vision- and life-threatening form of eye
cancer where standard of care with radiotherapy leaves patients
with severe comorbidities, including major vision loss. Aura plans
to develop AU-011 across its ocular oncology franchise including
for the treatment of patients with choroidal metastases. In
addition, leveraging Aura’s technology platform, Aura is developing
AU-011 more broadly across multiple cancers, starting with a
planned Phase 1 clinical trial in patients with non-muscle invasive
bladder cancer. Aura is headquartered in Cambridge, MA.
For more information, visit aurabiosciences.com, or follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220525005111/en/
Investor and Media Contact: Matthew DeYoung Argot
Partners 212-600-1902 | aura@argotpartners.com
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Apr 2023 to Apr 2024